Recent Advances in Erythropoietic Agents in Renal Anemia

Seminars in Nephrology

Volumn 26, Issue 4, 2006, Pages 313-318

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

anaemia; biosimilars; CERA; darbepoetin alfa; epoetin; Hematide; HIF stabilisers; novel erythropoietic agents

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ENZYME INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN FUSION PROTEIN; HEMATIDE; HEMATOPOIETIC CELL PHOSPHATASE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEPTIDE DERIVATIVE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN; PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SYNTHETIC ERYTHROPOIESIS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CLINICAL TRIAL; DEVELOPMENT; ERYTHROCYTE; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; GENE EXPRESSION; GENE THERAPY; HUMAN; IMMUNOGENICITY; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; RENAL ANEMIA; UPREGULATION;

ANEMIA; ENZYME INHIBITORS; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY FAILURE, CHRONIC; PEPTIDES; POLYETHYLENE GLYCOLS; PROCOLLAGEN-PROLINE DIOXYGENASE; UP-REGULATION;

EID: 33750868502     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.05.008     Document Type: Article

References (36)

1. Caro J., Brown S., Miller O., et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93 (1979) 449-458
2. Erslev A.J., and Besarab A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 126 (1995) 283-286
3. Alexanian R., Vaughn W.K., and Ruchelman M.W. Erythropoietin excretion in man following androgens. J Lab Clin Med 70 (1967) 777-785
4. Miyake T., Kung C.K., and Goldwasser E. Purification of human erythropoietin. J Biol Chem 252 (1977) 5558-5564
5. Lin F.K., Suggs S., Lin C.H., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82 (1985) 7580-7584
6. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 suppl 1 (2001) 3-10
7. Macdougall I.C., Gray S.J., Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 (1999) 2392-2395
8. Vanrenterghem Y., Barany P., Mann J.F., et al., European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62 (2002) 2167-2175
9. Nissenson A.R., Swan S.K., Lindberg J.S., et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 110-118
10. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002) 469-475
11. Committee for Proprietary Medicinal Products. Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance. Quality Issues (2003), Evaluation of Medicines for Human Use, The European Agency for the Evaluation of Medicinal Products, London
12. Schellekens H. Follow-on biologics: Challenges of the 'next generation.'. Nephrol Dial Transplant 20 suppl 4 (2005) iv31-iv36
13. Macdougall I.C. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4 (2005) 436-440
14. Haselbeck A., Bailon P., Pahlke W., et al. The discovery and characterization of CERA, an innovative agent for the treatment of anemia. Blood 100 (2002) 227A (abstr)
15. Dougherty F.C., Reigner B., Jordan P., et al. CERA (continuous erythropoiesis receptor activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. J Clin Oncol 22 (2004) 14S (abstr, suppl 15).
16. Macdougall I.C., Robson R., Opatrna S., et al. Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease patients following intravenous and subcutaneous administration. J Am Soc Nephrol 16 (2005) 759A
17. de Francisco A.L., Sulowicz W., and Dougherty F.C. Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: An exploratory multiple-dose study. J Am Soc Nephrol 14 (2003) 27A-28A (abstr).
18. Provenzano R., Besarab A., Macdougall I.C., et al., BA16528 Study Group. CERA (continuous erythropoietin receptor activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. J Am Soc Nephrol 15 (2004) 544A (abstr)
19. Besarab A., Bansal V., Fishbane S., et al., BA16285 Study Group. Intravenous CERA (continuous erythropoiesis receptor activator) administered once weekly or once every 2 weeks maintain haemoglobin levels in haemodialysis patients with chronic renal anaemia. Abstract Book of the XLI Congress of the ERA-EDTA 230 (2004) (abstr)
20. Locatelli F., Villa G., Arias M., et al., BA16286 Study Group. CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks. J Am Soc Nephrol 15 (2004) 543A (abstr)
21. Dmoszynska A., Kloczko J., Rokicka M., et al. CERA (continuous erythropoietin receptor activator) in patients with multiple myeloma: An exploratory phase I-II dose escalation study. J Clin Oncol 22 suppl 15 (2004) 14S
22. Wrighton N.C., Farrell F.X., Chang R., et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273 (1996) 458-464
23. Woodburn K., Fan Q., Holmes C.P., et al. Preclinical evaluation of Hematide™, a novel erythropoietic receptor agonist for the treatment of anemia caused by kidney disease. Blood 104 (2004) (abstr)
24. ™, a peptidic erythropoiesis stimulating agent that corrects anemia induced by partial nephrectomy and erythropoietin-specific antibodies in rats. Abstract presented at European Haematology Association, Stockholm, June, 2005
25. Stead R, Lambert J, Wessels D, et al: Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates dose dependent activity in a phase 1 single dose, dose escalating study in normal healthy volunteers. Abstract presented at European Haematology Association, Stockholm, June, 2005
26. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5 (2004) 343-354
27. Urquilla P., Fong A., Oksanen S., et al. Upregulation of endogenous EPO in healthy subjects by inhibition of HIF-PH. J Am Soc Nephrol 15 (2004) 546A
28. Wiecek A., Piecha G., Ignacy W., et al. Pharmacological stabilization of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease. Nephrol Dial Transplant 20 suppl 5 (2005) v195
29. Maxwell P. HIF-1: An oxygen response system with special relevance to the kidney. J Am Soc Nephrol 14 (2003) 2712-2722
30. Kochendoerfer G.G., Chen S.Y., Mao F., et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299 (2003) 884-887
31. Sytkowski A.J., Lunn E.D., Risinger M.A., et al. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274 (1999) 24773-24778
32. Qureshi S.A., Kim R.M., Konteatis Z., et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci U S A 96 (1999) 12156-12161
33. Klingmuller U., Lorenz U., Cantley L.C., et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80 (1995) 729-738
34. Rivera V.M., Gao G.P., Grant R.L., et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105 (2005) 1424-1430
35. Schwenter F., Schneider B.L., Pralong W.F., et al. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 15 (2004) 669-680
36. Binley K., Askham Z., Iqball S., et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 100 (2002) 2406-2413